-
WHAT IS THE RIGHT COMPARATOR WHEN NO STANDARD EXISTS? A LIVING EVIDENCE APPROACH TO JCA PLANNING IN EARLY-STAGE PROSTATE CANCER
Aug 11, 2026, 17:15 PM -
AVERAGE SALES PRICE AS A FAIRER BENCHMARK FOR MOST-FAVORED-NATION DRUG PRICING: A US-CANADA-GERMANY SPECIALTY-DRUG BASKET ANALYSIS
Aug 11, 2026, 17:15 PM -
FIVE CLINICALLY DISTINCT CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) PRESCRIBER PERSONAS IDENTIFIED VIA UNSUPERVISED MACHINE LEARNING USING NORSTELLALINQ REAL-WORLD DATA
Aug 11, 2026, 17:15 PM -
THE COVIDENCE RELEVANCE RANKING TOOL FOR ACCELERATING SCREENING IN LITERATURE REVIEWS
Aug 11, 2026, 17:15 PM -
FROM POLICY RECOGNITION TO IMPLEMENTATION READINESS: A GLOBAL ANALYSIS OF NATIONAL BREAST CANCER CONTROL POLICIES ACROSS 194 WHO MEMBER STATES
Aug 11, 2026, 17:15 PM -
BUILDING TRUST IN REAL-WORLD EVIDENCE: VALIDATION OF DATA, METHODS AND AI SOLUTIONS IN EUROPEAN CANCER CENTRES
Aug 11, 2026, 17:15 PM -
WHY IS CAREGIVER HEALTH-RELATED QUALITY OF LIFE STILL EXCLUDED FROM CANCER HEALTH TECHNOLOGY ASSESSMENT?
Aug 11, 2026, 17:15 PM -
AN UNANCHORED MATCHING-ADJUSTED INDIRECT COMPARISON OF OVERALL SURVIVAL WITH RETIFANLIMAB PLUS CARBOPLATIN-PACLITAXEL VERSUS CARBOPLATIN-PACLITAXEL IN ADVANCED SQUAMOUS CELL ANAL CARCINOMA
Aug 11, 2026, 17:15 PM -
THE COST-EFFECTIVENESS GAP: PHYSICIANS' PERCEPTIONS, KNOWLEDGE, AND WHERE TO GO FROM HERE
Aug 11, 2026, 17:15 PM -
BIUX2X2
Aug 11, 2026, 17:15 PM -
REAL-WORLD EPIDEMIOLOGY, TREATMENT PATTERNS, AND CLINICAL OUTCOMES OF METASTATIC COLORECTAL CANCER IN TAIWAN: A NATIONWIDE POPULATION-BASED STUDY, 2015-2021
Aug 11, 2026, 17:15 PM -
THE IMPACT OF CLINICAL RESEARCH INVESTMENT ON HEALTHCARE RESOURCE UTILIZATION AND COST OUTCOMES
Aug 11, 2026, 17:15 PM -
AUTOMATING QUALITY ASSESSMENT: AGREEMENT BETWEEN AI AND HUMAN CRITICAL APPRAISAL USING THE NEWCASTLE-OTTAWA SCALE
Aug 11, 2026, 17:15 PM -
BUDGET IMPACT OF A LONG-TERM AMBULATORY ECG MONITORING PATCH (ZIO XT) COMPARED WITH HOLTER MONITORING IN ENGLAND
Aug 11, 2026, 17:15 PM -
NATIONAL INDICATION RESTRICTIONS ACROSS EUROPE: DO THEY EXPLAIN CROSS-NATIONAL ACCESS DISPARITIES FOR INNOVATIVE MEDICINES? (2021-2025)
Aug 11, 2026, 17:15 PM -
GENE THERAPY AUTHORIZATIONS AND ORPHAN DRUG DESIGNATIONS BY THE FDA AND EMA
Aug 11, 2026, 17:15 PM -
FACTORS ASSOCIATED WITH SGLT2 INHIBITOR INITIATION IN NEWLY DIAGNOSED TYPE 2 DIABETES PATIENTS: A REAL-WORLD ANALYSIS FROM GERMAN PRIMARY CARE
Aug 11, 2026, 17:15 PM -
MICROSIMULATION OF THE NATURAL HISTORY OF STAGE II/III COLORECTAL CANCER AND EVALUATION OF FOLLOW-UP TESTING STRATEGIES (MONET-MODEL)
Aug 11, 2026, 17:15 PM -
COST-EFFECTIVENESS OF PRE-TREATMENT COMPREHENSIVE GENOMIC PROFILING IN ADVANCED COLORECTAL CANCER: A JAPANESE PAYER PERSPECTIVE
Aug 11, 2026, 17:15 PM -
A FIVE-DIMENSIONAL CONCEPTUAL FRAMEWORK FOR ANALYSING PAYMENT MODELS FOR DIGITAL HEALTH TECHNOLOGIES: DEVELOPMENT AND EXPERT VALIDATION
Aug 11, 2026, 17:15 PM
